The production of IgA by B-cells is believed to underlie the pathogenesis of IgA nephropathy (IgAN), and several modulators of B-cell IgA production are now being explored as potential therapeutic targets. Don’t miss the opportunity to hear two renowned experts in IgAN discuss this novel therapeutic class and review the latest clinical evidence for emerging B-cell directed agents being developed as treatments for IgAN. Through this educational activity, you have the opportunity to earn a maximum of 2.5 CE credits in total. To achieve this, you can complete the PRIME on-demand video to earn 0.5 CE credits. Additionally, if you choose to engage with the SynopsiMedEd Related Evidence articles, you can earn an extra 2 CE credits. If you decide not to engage with these articles, you can still claim partial credit based on your level of participation. Total Possible Credits: 2.5 CE Credits from PRIME On-Demand Video: 0.5 CE Credits from SynopsiMedEd Related Evidence: 2 CE
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/emerging-b-cell-targeted-therapies-iga-nephropathy
- Start Date: 2024-09-27 05:00:00
- End Date: 2024-09-27 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 2.5 hours
AMA PRA Category 1 Credit™️: 2.5 hours
Nursing: 2.5 hours
Pharmacy: 2.5 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 12500.0 - Is Kind Support: False Source: Otsuka America Pharmaceutical, Inc. - Amount: 18625.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all